Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Tolerability of Atabecestat in Early Alzheimer's Disease
NCT02260674Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 6
01
Overview
A Phase 2 trial of atabecestat in Alzheimer's disease (AD), sponsored by Janssen Pharmaceutical. Started Nov 2014; status: completed.
02
Drugs
atabecestat
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02260674.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02260674.